CD205

Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

Retrieved on: 
Thursday, January 18, 2024
Hope, OBT, Neoplasm, Patient, Radiation therapy, MD, ADC, Neck, PD-1, Radiation, Head, NSCLC, ACC, Doctor of Philosophy, Antigen, Ovarian cancer, Lausanne University Hospital, Lung, CPI, CD205, Pharmaceutical industry

OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.

Key Points: 
  • OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients.
  • The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need, including gastric, lung and ovarian cancer.
  • We look forward to demonstrating the potential value of OBT076, with the hope to provide meaningful benefit for ACC patients.
  • Trial arms are investigating OBT076 both as a monotherapy and in combination with a CPI in these tumors.

Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe

Retrieved on: 
Wednesday, July 5, 2023
Partnership, AACR, PD, Therapy, CPI, Neoplasm, HER2, Infection, American Society of Clinical Oncology, Pharmacokinetics, American Association for Cancer Research, OBT, CD205, NSCLC, Part, Doctor of Philosophy, Lung, ASCO, Primary tumor, Patient, Data, Phases of clinical research, Immune system, Cancer, ADC, Ovarian cancer, Pembrolizumab, Society, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Agenus

OBT initiates clinical combination study for both CPI-naïve and resistant patients with advanced solid tumors by dosing first patient with OBT076 in combination with checkpoint inhibitor (CPI) balstilimab.

Key Points: 
  • OBT initiates clinical combination study for both CPI-naïve and resistant patients with advanced solid tumors by dosing first patient with OBT076 in combination with checkpoint inhibitor (CPI) balstilimab.
  • This extension of OBT’s US Phase I Clinical Trial for OBT076 will evaluate the clinical efficacy of OBT076 in combination with balstilimab in patients with solid tumors including lung, gastric and ovarian cancer.
  • This extension is designed to build on preliminary data supporting OBT076’s ability to deliver immune priming in chemo-refractory, advanced cancer patients.
  • OBT has also expanded its Phase 1b clinical trial investigating the safety, tolerability and pharmacokinetic profile of OBT076 as a monotherapy in Europe.

Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck

Retrieved on: 
Wednesday, April 19, 2023
Learning, ACC, Partnership, CPI, Neoplasm, OBT, Head, Lausanne University Hospital, NSCLC, Radiation therapy, Doctor of Philosophy, Neck, Radiation, MD, Patient, Risk, CD205, ADC, PD-1, Recurrence, Adenoid cystic carcinoma, Metastasis, Disease, Pharmaceutical industry

ACC is a rare, aggressive type of cancer which represents 2% of head and neck cancers and about 20% of salivary gland malignancies.

Key Points: 
  • ACC is a rare, aggressive type of cancer which represents 2% of head and neck cancers and about 20% of salivary gland malignancies.
  • OBT has observed the drug receptor CD205, a unique characteristic for this disease, in at least 80% of ACC patients.
  • CD205 is the target for OBT’s innovative ADC, OBT076, suggesting that OBT076 may have high therapeutic potential in this type of cancer.
  • It will investigate OBT076 both as a monotherapy and in combination with Agenus Inc. proprietary checkpoint inhibitor (CPI), balstilimab.

Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at World ADC Conference 2023

Retrieved on: 
Thursday, March 9, 2023
Proteomics, CD205, Immune system, ImmunoGen, OBT, Research, Cancer, Abstract, Growth, American Association for Cancer Research, CPI, ADC, Patient, Therapy, Drug design, Spacecraft, AACR, Partnership, Science, Conference, Fine chemical, Pharmaceutical industry, Vaccine

Oxford, UK and San Jose, Calif., 9 March 2023 - Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced it will reveal its new fully integrated ADC engine, combining its internationally recognised target discovery and ADC development capabilities, at the 13th Annual World ADC Conference being held in London, UK, from 13 to 16 March 2023.

Key Points: 
  • Oxford, UK and San Jose, Calif., 9 March 2023 - Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced it will reveal its new fully integrated ADC engine, combining its internationally recognised target discovery and ADC development capabilities, at the 13th Annual World ADC Conference being held in London, UK, from 13 to 16 March 2023.
  • “I am delighted to announce OBT’s novel, fully integrated ADC engine, which brings together our internal capabilities in target discovery and drug design and development,” said Christian Rohlff, CEO, Oxford BioTherapeutics.
  • “We are very pleased to have a significant company presence at this year’s World ADC Conference and to present abstracts highlighting our proprietary OGAP® platform and our ADC collaboration with ImmunoGen.
  • The two World ADC Conference abstracts describe the latest high-impact outputs from OBT’s proprietary proteomic database OGAP® and its ongoing collaboration with ImmunoGen to develop multiple, first-in-class ADCs.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Retrieved on: 
Monday, October 3, 2022
Cancer, ADCC, Doctor of Philosophy, ADC, Neoplasm, CD205, Boehringer Ingelheim, Clinical trial, Rhode Island Division of Commercial Licensing and Regulation, Antibody-drug conjugate, CEO, Amgen, NJ, Kite Pharma, Cytotoxicity, BMS, OXFORD, SAN, Patient, OBT, Wuxi, Therapy, Vaccine, IO

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Key Points: 
  • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.
  • OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.
  • Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody.
  • This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Retrieved on: 
Monday, October 3, 2022
Cancer, ADCC, Doctor of Philosophy, ADC, Neoplasm, CD205, Boehringer Ingelheim, Clinical trial, Rhode Island Division of Commercial Licensing and Regulation, Antibody-drug conjugate, CEO, Amgen, NJ, Kite Pharma, Cytotoxicity, BMS, OXFORD, SAN, Patient, OBT, Wuxi, Therapy, Vaccine, IO

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Key Points: 
  • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.
  • OBT will receive an undisclosed upfront and potential milestone payments and royalty payments on net product sales under the agreement.
  • Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody.
  • This represents the first major license agreement for OBT's IO programs to a world leader in the field of antibody-based oncology medicines.

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Cancer, Ascites, Part, Achievement, Company, Neutropenia, BMS, Neoplasm, CPI, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, OXFORD, Pharmacokinetics, Society, American Society of Clinical Oncology, Cmax, Adult, SAN, DLT, Clinical trial, GCSF, Toxicity, CD205, Safety, HIV disease progression rates, Cytotoxicity, ASCO, Boehringer Ingelheim, Lung, Therapy, PD, OBT, Immune system, Infrared spectroscopy correlation table, Amgen, CEO, ADCC, Granulocyte, Pharmaceutical industry, Medical imaging, Fine chemical, IO

Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.

Key Points: 
  • Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
  • Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Cancer, Ascites, Part, Achievement, Company, Neutropenia, BMS, Neoplasm, CPI, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, OXFORD, Pharmacokinetics, Society, American Society of Clinical Oncology, Cmax, Adult, SAN, DLT, Clinical trial, GCSF, Toxicity, CD205, Safety, HIV disease progression rates, Cytotoxicity, ASCO, Boehringer Ingelheim, Lung, Therapy, PD, OBT, Immune system, Infrared spectroscopy correlation table, Amgen, CEO, ADCC, Granulocyte, Pharmaceutical industry, Medical imaging, Fine chemical, IO

Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.

Key Points: 
  • Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
  • Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

Retrieved on: 
Wednesday, May 25, 2022
Cancer, Company, BMS, Neoplasm, CPI, Infection, CD205, GMP, ImmunoGen, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, PD-1, OXFORD, Primary tumor, Therapy, Clinical trial, Mink, Research, SAN, Partnership, Ovarian cancer, Boehringer Ingelheim, Lung, CMO, Twitter, Immune system, Amgen, OBT, MD, CA, CEO, Pharmaceutical industry, Medical imaging, Vaccine, IO

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.

Key Points: 
  • OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.
  • Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.
  • "I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.
  • "We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O'Day, MD, Chief Medical Officer of Agenus.

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

Retrieved on: 
Wednesday, May 25, 2022
Cancer, Company, BMS, Neoplasm, CPI, Infection, CD205, GMP, ImmunoGen, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, PD-1, OXFORD, Primary tumor, Therapy, Clinical trial, Mink, Research, SAN, Partnership, Ovarian cancer, Boehringer Ingelheim, Lung, CMO, Twitter, Immune system, Amgen, OBT, MD, CA, CEO, Pharmaceutical industry, Medical imaging, Vaccine, IO

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.

Key Points: 
  • OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.
  • Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.
  • "I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.
  • "We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O'Day, MD, Chief Medical Officer of Agenus.